Meanwhile, serum albumin was also related to a decreased risk of PD-related death after adjustment for age, sex, mHY stage, PD disease duration, CRP, MMSE, and use of NSAIDs, with a median follow-up of 5.24 years; also, this relationship was more significant in older (≥65 years) or male patients, as well as patients with prolonged PD disease duration (7–29 years) ad a higher CRP baseline level (≥5 mg/L) when serum albumin was between 4.2 and 5.1 mg/dL. This evidence concerns the gene CRP and Parkinson disease.